Mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed and/or refractory follicular lymphoma after ≥ 2 prior therapies including those with a history of POD24: 4-year follow-up of a pivotal phase II study Meeting Abstract
| Authors: | Shadman, M.; Bartlett, N. L.; Matasar, M.; Schuster, S. J.; Assouline, S. E.; Sehn, L. H.; Kuruvilla, J.; Giri, P.; Cheah, C. Y.; Dietrich, S.; Fay, K.; Ku, M.; Nastoupil, L.; Wei, M. C.; Yin, S.; Ma, C. Y.; Tracy, S.; Kwan, A.; Penuel, E.; Budde, L. E. |
| Abstract Title: | Mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed and/or refractory follicular lymphoma after ≥ 2 prior therapies including those with a history of POD24: 4-year follow-up of a pivotal phase II study |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 4408 |
| End Page: | 4409 |
| Language: | English |
| ACCESSION: | WOS:001409330600042 |
| DOI: | 10.1182/blood-2024-197897 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
